RxLink Pharmaceuticals RxLink Pharmaceuticals Pharmaceutical Innovations for the Future R & D RxLink Pharmaceuticals R & D West Palm Beach, FL May 3, 2022 – The FDA approved a REMS Modification, and SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX tablets are now covered under the Buprenorphine-containing Transmucosal products for Opioid Dependence (BTOD) REMS Program. Twitter Contact RxLink Let us know how to get back to you. First Name * Last Name * Email Address Phone Number * How can we help? Feel free to ask a question or simply leave a comment. Comments / Questions *